Citius Oncology's LYMPHIR Shows Early Promise in Gynecologic Cancer Trial
Event summary
- Citius Oncology presented Phase 1 data at ASCO 2026 showing LYMPHIR + pembrolizumab achieved 24% ORR in heavily pre-treated gynecologic cancer patients.
- Median progression-free survival was 20.5 months among patients achieving clinical benefit.
- 33% ORR observed in endometrial cancer patients previously treated with checkpoint inhibitors.
- No maximum tolerated dose achieved; safety profile deemed manageable in heavily pre-treated population.
The big picture
Citius Oncology's data suggests potential for LYMPHIR to address a significant unmet need in recurrent gynecologic cancers where checkpoint inhibitors often fail. The combination approach targets immune resistance in the tumor microenvironment, aligning with broader industry trends toward immuno-modulatory therapies. With LYMPHIR's current approval in cutaneous T-cell lymphoma, positive results in this new indication could expand its market potential significantly.
What we're watching
- Clinical Validation
- Whether the durable responses observed in this small Phase 1 study will translate to larger, more definitive trials.
- Regulatory Pathway
- The pace at which Citius Oncology can advance this combination therapy through subsequent clinical phases given its current investigational status.
- Competitive Positioning
- How this data positions LYMPHIR in the growing market for immuno-oncology combinations targeting checkpoint inhibitor resistance.
Related topics